AuthorBartsMSBlog

Anti-drug antibody awareness: HCP survey

Hello, my name is Farhana and I am a third year Biomedical Sciences student at Queen Mary University of London. I was born and brought up in Rome and moved to the UK when I was 12 where I completed my GCSE and A-Levels. After completing my degree, I am hoping to study medicine and become a doctor specialising in neuroscience or paediatrics. I am hoping work around the world as my ambition to...

Managing Multiple Sclerosis (MS) and its Co-morbidities

My name is Sumayyah and as a part of my final year research project I am on a 12-week placement with the aim of planning and designing patient information in a form that is accessible to many MS patients. This is to help them manage their co-morbidities alongside their MS. Co-morbidity means having more than one disease or condition at the same time as a disease of interest i.e. other...

Optic Neuritis App Development survey

Hello, my name is David and I’m a final year Biomedical Science student at Queen Mary University of London. I was born in Lagos, Nigeria and brought up in Middlesbrough, located in the north east of England. After my current degree I hope to study medicine and specialise as an ophthalmologist. My interest in ophthalmology grew as a result of my part time work at King’s College Hospital’s...

Guest Post:Cell Therapies to Treat Viral Infections

Today we are delighted to have a guest post by Dr Chris Lazarski to talk about their interesting work. Background: Vaccines are a critical tool to protect the majority of people from viral infection.  However, some people require a more involved treatment strategy to treat persistent viral infections.  These people may be immune suppressed because they have received a bone marrow...

Fractured

On Saturday Professor Giovannoni was involved in an accident and sustained a minor head injury, fractured cervical spine, fractured pelvis and several soft tissue contusions. He was struck by a motorcycle travelling at high-speed whilst he was out running. As a result, he will be off work for several weeks and is likely to return to work in January 2021 or later after a period of rehabilitation...

Barts-MS Journal Club 28-Sept-2020

The following is our journal club from 28th September and was presented by Dr Ben Jacobs. Briggs et al. Nicotinic acetylcholine receptors α7 and α9 modifies tobacco smoke risk for multiple sclerosis. MSJ First Published September 14, 2020 Research Article Introduction: Tobacco smoke exposure is an established risk factor for multiple sclerosis (MS), yet how it confers risk is not known. Evidence...

Brain microglial activity predicts faster progression of MS

Prof Laura Airas is based in Turku PET Centre, Turku, Finland and writes about their recent paper. Disclosures  She has received honoraria from Biogen, Roche., Genzyme, Merck Serono and Teva, and institutional research grant support from Finnish Academy, Sigrid Juselius Foundation, Nancy Davis Foundation, Biogen, Genzyme, Merck Serono and Novartis. Prof Laura Airas writes Brain microglial...

Journal Club: whack-a-mole

The latest Barts-MS journal club describes and discusses the Whack-A-Mole strategy dealing with secondary autoimmunity post-alemtuzumab treatment. It is based on the paper below. Meltzer et al. Mitigating alemtuzumab-associated autoimmunity in MS: A “whack-a-mole” B-cell depletion strategy. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 7;7(6):e868. doi: 10.1212/NXI.0000000000000868...

Journal Club: Early vs. Late or Low vs. High efficacy

You are welcome to watch our online journal club discussing the following paper. Anna He et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 2020 Apr;19(4):307-316.Background: High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line disease modifying therapies. We...

Translate

Categories

Recent Posts

Recent Comments

Archives